Research Articles
Research articles concerning NAFLD are extracted from PubMed. For each individual article, related therapeutic strategies, targets, drugs and associated diseases in NAFLDkb are presented with knowledge graphs.
stats1
stats2
stats3
stats4
Search for:
Orlistat74 records.
| Article ID | PMID | Source | Title | Publish Year | |
|---|---|---|---|---|---|
| A00880 | 34943134 | Antioxidants (Basel) | Hepatoprotective Effect of Bee Bread in Metabolic Dysfunction-Associated Fatty Liver Disease (MAFLD) Rats: Impact on Oxidative Stress and Inflammation. | 2021 | Details |
| A01224 | 34822647 | Vet Sci | Protective and Therapeutic Effects of Orlistat on Metabolic Syndrome and Oxidative Stress in High-Fat Diet-Induced Metabolic Dysfunction-Associated Fatty Liver Disease (MAFLD) in Rats: Role on Nrf2 Activation. | 2021 | Details |
| A01882 | 34574082 | Foods | AGL9: A Novel Hepatoprotective Peptide from the Larvae of Edible Insects Alleviates Obesity-Induced Hepatic Inflammation by Regulating AMPK/Nrf2 Signaling. | 2021 | Details |
| A04332 | 33664007 | Arab J Gastroenterol | Short-term orlistat therapy improves fatty infiltration indices and liver fibrosis scores in patients with non-alcoholic fatty liver disease and metabolic syndrome. | 2021 | Details |
| A05930 | 33072533 | Adv Pharm Bull | The Evaluation of Effective Drugs for the Treatment of Non-Alcoholic Fatty Liver Disease: A Systematic Review and Network Meta-Analysis. | 2020 | Details |
| A08318 | 32153507 | Front Endocrinol (Lausanne) | Effect of Weight Loss Medications on Hepatic Steatosis and Steatohepatitis: A Systematic Review. | 2020 | Details |
| A08596 | 32045588 | Toxicol Appl Pharmacol | Orlistat delays hepatocarcinogenesis in mice with hepatic co-activation of AKT and c-Met. | 2020 | Details |
| A08925 | 31935815 | Int J Mol Sci | Antrodan Alleviates High-Fat and High-Fructose Diet-Induced Fatty Liver Disease in C57BL/6 Mice Model via AMPK/Sirt1/SREBP-1c/PPARγ Pathway. | 2020 | Details |
| A09503 | 31717842 | Nutrients | Efficacy and Mechanism of Polymerized Anthocyanin from Grape-Skin Extract on High-Fat-Diet-Induced Nonalcoholic Fatty Liver Disease. | 2019 | Details |
| A09731 | 31632457 | Therap Adv Gastroenterol | Effect of orlistat on liver fat content in patients with nonalcoholic fatty liver disease with obesity: assessment using magnetic resonance imaging-derived proton density fat fraction. | 2019 | Details |
| A12076 | 30611993 | Biomed Pharmacother | Plumbagin reduces obesity and nonalcoholic fatty liver disease induced by fructose in rats through regulation of lipid metabolism, inflammation and oxidative stress. | 2019 | Details |
| A12313 | 30502373 | Metabolism | Obesity and nonalcoholic fatty liver disease: From pathophysiology to therapeutics. | 2018 | Details |
| A12474 | 30431378 | Curr Med Res Opin | Severe nonalcoholic steatohepatitis and type 2 diabetes: liver histology after weight loss therapy in a randomized clinical trial. | 2018 | Details |
| A13421 | 29986142 | J Med Chem | Monoacylglycerol Acyltransferase 2 (MGAT2) Inhibitors for the Treatment of Metabolic Diseases and Nonalcoholic Steatohepatitis (NASH). | 2018 | Details |
| A13525 | 29930810 | Biomed Rep | Efficacy of orlistat in non-alcoholic fatty liver disease: A systematic review and meta-analysis. | 2018 | Details |
| A14840 | 29209440 | EPMA J | Efficacy of Fenugreek-based bionanocomposite on renal dysfunction and endogenous intoxication in high-calorie diet-induced obesity rat model-comparative study. | 2017 | Details |
| A15798 | 28705172 | BMC Endocr Disord | Endocannabinoid receptor blockade reduces alanine aminotransferase in polycystic ovary syndrome independent of weight loss. | 2017 | Details |
| A16464 | 28372259 | Biomed Pharmacother | Medicinal plants and phytochemicals with anti-obesogenic potentials: A review. | 2017 | Details |
| A16657 | 28260907 | Ther Clin Risk Manag | Effect of orlistat on periostin, adiponectin, inflammatory markers and ultrasound grades of fatty liver in obese NAFLD patients. | 2017 | Details |
| A16753 | 28209193 | BMC Complement Altern Med | UP601, a standardized botanical composition composed of Morus alba, Yerba mate and Magnolia officinalis for weight loss. | 2017 | Details |
| A17622 | 27711029 | Minerva Endocrinol | Adipose tissue, obesity and non-alcoholic fatty liver disease. | 2016 | Details |
| A17704 | 27646933 | Gut | Current and upcoming pharmacotherapy for non-alcoholic fatty liver disease. | 2016 | Details |
| A18078 | 27363235 | Adolesc Med State Art Rev | Gastrointestinal Conditions in the Obese Patient. | 2016 | Details |
| A18539 | 27063274 | Clin Liver Dis | Current Pharmacologic Therapy for Nonalcoholic Fatty Liver Disease. | 2016 | Details |
| A20890 | 25659874 | Atheroscler Suppl | The effect of ezetimibe on NAFLD. | 2015 | Details |
| A21508 | 25267322 | Aliment Pharmacol Ther | Review article: the management of paediatric nonalcoholic fatty liver disease. | 2014 | Details |
| A22819 | 24287794 | Endocrine | Non-alcoholic fatty liver disease: a diabetologist's perspective. | 2013 | Details |
| A22925 | 24206433 | Aliment Pharmacol Ther | Systematic review with meta-analysis: non-alcoholic steatohepatitis - a case for personalised treatment based on pathogenic targets. | 2013 | Details |
| A23081 | 24059726 | Mini Rev Med Chem | Hepatic diseases related to triglyceride metabolism. | 2013 | Details |
| A24973 | 22291824 | Arch Med Sci | Safety and impact on cardiovascular events of long-term multifactorial treatment in patients with metabolic syndrome and abnormal liver function tests: a post hoc analysis of the randomised ATTEMPT study. | 2011 | Details |
| A25240 | 22059109 | World J Hepatol | Role of ezetimibe in non-alcoholic fatty liver disease. | 2011 | Details |
| A25591 | 21678341 | Cochrane Database Syst Rev | Weight reduction for non-alcoholic fatty liver disease. | 2011 | Details |
| A26054 | 21160985 | World J Hepatol | Combination drug treatment in patients with non-alcoholic fatty liver disease. | 2010 | Details |
| A26404 | 23148155 | Ther Adv Endocrinol Metab | Advances in the treatment of nonalcoholic fatty liver disease. | 2010 | Details |
| A26422 | 20485253 | Minerva Gastroenterol Dietol | Weight loss: cornerstone in the treatment of non-alcoholic fatty liver disease. | 2010 | Details |
| A26478 | 20415685 | Diabetes Obes Metab | The role of adiponectin in the pathogenesis and treatment of non-alcoholic fatty liver disease. | 2010 | Details |
| A26483 | 20388946 | J Physiol Pharmacol | Therapy of nonalcoholic fatty liver disease: current status. | 2009 | Details |
| A26531 | 20353583 | J Inflamm (Lond) | Elevated endotoxin levels in non-alcoholic fatty liver disease. | 2010 | Details |
| A26761 | 19818312 | Clin Liver Dis | Pharmacologic therapy of non-alcoholic steatohepatitis. | 2009 | Details |
| A27087 | 19199918 | Curr Med Chem | Obesity: pathophysiology and clinical management. | 2009 | Details |
| A27218 | 18956296 | Semin Liver Dis | Current and emerging therapies in nonalcoholic fatty liver disease. | 2008 | Details |
| A27543 | 18095746 | Drug Saf | Orlistat-associated adverse effects and drug interactions: a critical review. | 2008 | Details |
| A28016 | 16709309 | Curr Med Res Opin | Effect of multifactorial treatment on non-alcoholic fatty liver disease in metabolic syndrome: a randomised study. | 2006 | Details |
| A28037 | 16630771 | Clin Gastroenterol Hepatol | A double-blind randomized placebo-controlled trial of orlistat for the treatment of nonalcoholic fatty liver disease. | 2006 | Details |
| A28062 | 16540766 | J Clin Gastroenterol | Weight loss as a treatment for nonalcoholic fatty liver disease. | 2006 | Details |
| A28346 | 15561641 | Best Pract Res Clin Gastroenterol | Non-alcoholic fatty liver disease/non-alcoholic steatohepatitis (NAFLD/NASH): treatment. | 2004 | Details |
| A28376 | 15333967 | Indian J Gastroenterol | Efficacy of omega-3 fatty acids, atorvastatin and orlistat in non-alcoholic fatty liver disease with dyslipidemia. | 2004 | Details |
| A32715 | 27699065 | J Obes | Appetite Suppression and Antiobesity Effect of a Botanical Composition Composed of Morus alba, Yerba mate, and Magnolia officinalis. | 2016 | Details |
| A36714 | 17404856 | Dig Dis Sci | Orlistat reverse fatty infiltration and improves hepatic fibrosis in obese patients with nonalcoholic steatohepatitis (NASH). | 2007 | Details |
| A37563 | 15352910 | Aliment Pharmacol Ther | A pilot study of orlistat treatment in obese, non-alcoholic steatohepatitis patients. | 2004 | Details |
| A37841 | 14502318 | Rom J Gastroenterol | The effects of sibutramine and orlistat on the ultrasonographic findings, insulin resistance and liver enzyme levels in obese patients with non-alcoholic steatohepatitis. | 2003 | Details |
| A37934 | 12738478 | Am J Gastroenterol | Orlistat in the treatment of NASH: a case series. | 2003 | Details |
| A43171 | 32378399 | J Obes Metab Syndr | Current Long-Term Pharmacotherapies for the Management of Obesity. | 2020 | Details |
| A44051 | 30034597 | ACS Med Chem Lett | Discovery of Natural Product Derived Labdane Appended Triazoles as Potent Pancreatic Lipase Inhibitors. | 2018 | Details |
| A46396 | 19053049 | Hepatology | Orlistat for overweight subjects with nonalcoholic steatohepatitis: A randomized, prospective trial. | 2009 | Details |
| A46432 | 18685459 | Curr Opin Clin Nutr Metab Care | Nutrition in pathophysiology and treatment of nonalcoholic fatty liver disease. | 2008 | Details |
| A46503 | 18209783 | Can J Gastroenterol | Obesity: a review of pathogenesis and management strategies. | 2008 | Details |
| A46743 | 15989845 | Med Clin (Barc) | [Medical management of primary nonalcoholic fatty liver disease]. | 2005 | Details |
| A46799 | 15333965 | Indian J Gastroenterol | Treatment of hyperlipidemia in nonalcoholic fatty liver disease: fat for thought. | 2004 | Details |
| A46864 | 12230315 | Semin Gastrointest Dis | Medical management of obesity. | 2002 | Details |
| A47772 | 32191579 | J Med Food | Physalis alkekengi Exhibits Antiobesity Effects in Mice with Potential of Inducing White Adipose Tissue Browning. | 2020 | Details |
| A47939 | 28708468 | J Med Food | A Botanical Composition from Morus alba, Ilex paraguariensis, and Rosmarinus officinalis for Body Weight Management. | 2017 | Details |
| A48042 | 25866507 | Gastroenterol Res Pract | Treatment of nonalcoholic steatohepatitis in adults: present and future. | 2015 | Details |
| A48216 | 19492425 | Hepatology | Orlistat for overweight subjects with nonalcoholic steatohepatitis. | 2009 | Details |
| A48218 | 19475695 | Hepatology | Orlistat for overweight subjects with nonalcoholic steatohepatitis. | 2009 | Details |
| A49110 | 17339254 | Gut | Weight loss induced by orlistat reverses fatty infiltration and improves hepatic fibrosis in obese patients with non-alcoholic steatohepatitis. | 2007 | Details |
| A49252 | 35809408 | Comput Biol Med | In silico and in vitro analysis of PPAR - α / γ dual agonists: Comparative evaluation of potential phytochemicals with anti-obesity drug orlistat. | 2022 | Details |
| A49652 | 35678800 | Turk J Gastroenterol | Effects of Orlistat or Telmisartan on the Serum Free Fatty Acids in Non-alcoholic Fatty Liver Disease Patients: An Open-Labeled Randomized Controlled Study. | 2022 | Details |
| A50153 | 35501557 | Curr Obes Rep | Anti-obesity Medications for the Management of Nonalcoholic Fatty Liver Disease. | 2022 | Details |
| A50264 | 35449947 | ACS Omega | Polyphenol-Rich Extracts of Xylopia and Aframomum Species Show Metabolic Benefits by Lowering Hepatic Lipid Accumulation in Diet-Induced Obese Mice. | 2022 | Details |
| A50671 | 35307486 | Cancer Lett | Sperm associated antigen 4 promotes SREBP1-mediated de novo lipogenesis via interaction with lamin A/C and contributes to tumor progression in hepatocellular carcinoma. | 2022 | Details |
| A50792 | 35264693 | Sci Rep | Clitorin ameliorates western diet-induced hepatic steatosis by regulating lipogenesis and fatty acid oxidation in vivo and in vitro. | 2022 | Details |
| A51747 | 34408822 | Ther Adv Chronic Dis | Steatosis grading consistency between controlled attenuation parameter and MRI-PDFF in monitoring metabolic associated fatty liver disease. | 2021 | Details |
| A52961 | 18773755 | G Ital Cardiol (Rome) | [Pharmacological therapy of obesity]. | 2008 | Details |